scholarly journals Safety and Efficacy of PD-1 Inhibitors Plus Chemotherapy in Advanced Soft Tissue Sarcomas: A Retrospective Study

2020 ◽  
Vol Volume 12 ◽  
pp. 1339-1346 ◽  
Author(s):  
Zhichao Tian ◽  
Yonghao Yang ◽  
Jinpo Yang ◽  
Peng Zhang ◽  
Fan Zhang ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Safety And Efficacy

scholarly journals A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb‐004) in metastatic soft‐tissue sarcomas

Cancer ◽  
2019 ◽  
Vol 125 (14) ◽  
pp. 2445-2454 ◽  
Author(s):  
Robin L. Jones ◽  
Sant P. Chawla ◽  
Steven Attia ◽  
Patrick Schöffski ◽  
Hans Gelderblom ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Phase 1 ◽  
Soft Tissue Sarcomas ◽  
Phase 2 ◽  
Safety And Efficacy ◽  
Randomized Controlled ◽  
Phase 2 Trial

scholarly journals Clinicopathological study of soft tissue sarcoma-retrospective study of tertiary cancer institute in eastern India

2020 ◽  
Vol 8 (11) ◽  
pp. 4075
Author(s):  
Kunhi Mohammed K. P. ◽  
Snehasis Pradhan ◽  
Supratim Bhattacharyya ◽  
Prafulla Kumar Das ◽  
Muhammed Navas N. K.
Keyword(s):  
Retrospective Study ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Malignant Tumors ◽  
Soft Tissue Sarcomas ◽  
The Body ◽  
Female Ratio ◽  
Pleomorphic Sarcoma ◽  
Frequent Variety ◽  
Male To Female

Background: Soft tissue sarcomas are a rare and heterogeneous group of malignant tumors of mesenchymal origin that comprise less than 1 percent of all adult malignancies. Although they occur anywhere in the body, they involve most commonly in extremities, trunk, retroperitoneum and head and neck. The aim of the study was to analyze clinical and histopathological features of various soft tissue sarcomas.Methods: This was a retrospective study, conducted in tertiary cancer centre in Odisha during the period 2015 to 2018. We collected clinical parameters like age, sex, site of swelling, any associated pain and biopsy reports and these variables were correlated with final histopathology reports.Results: A total of 107 patients were included in the study, with male to female ratio of 2:1(71 and 36) and average age of 43.45 years. All of them presented with a swelling. The lower extremities were the most common sites i.e. 44.62%. Pleomorphic sarcoma was the most frequent histologic variety comprising 43% and less frequent variety were angiosarcoma, and myxoid sarcoma.Conclusions: Soft tissue sarcoma are predominant in males and middle aged population are frequently affected. Most common affected site is lower extremity and pleomorphic sarcoma is the prominent histologic type.

Management of soft tissue sarcomas (STS) in first isolated local recurrence: a retrospective study of 83 cases

2004 ◽  
Vol 73 (3) ◽  
pp. 313-319 ◽  
Author(s):  
Laurence Moureau-Zabotto ◽  
Laurence Thomas ◽  
Binh N'Guyen Bui ◽  
Christine Chevreau ◽  
Eberhard Stockle ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Soft Tissue ◽  
Local Recurrence ◽  
Soft Tissue Sarcomas ◽  
Isolated Local Recurrence

scholarly journals Retrospective study of the surgical management and outcome of nonrhabdomyosarcoma soft tissue sarcomas of the groin and axilla in children

2009 ◽  
Vol 44 (10) ◽  
pp. 1972-1976 ◽  
Author(s):  
Gideon Karplus ◽  
Matthew J. Krasin ◽  
Carlos Rodriguez-Galindo ◽  
Beth McCarville ◽  
Jesse Jenkins ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Soft Tissue ◽  
Surgical Management ◽  
Soft Tissue Sarcomas

Particle Therapy for Bone and Soft Tissue Sarcomas: A Retrospective Study

2009 ◽  
Vol 75 (3) ◽  
pp. S530
Author(s):  
Y. Demizu ◽  
M. Murakami ◽  
D. Miyawaki ◽  
M. Mima ◽  
K. Terashima ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Particle Therapy

scholarly journals Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas

JAMA Oncology ◽  
2020 ◽  
Vol 6 (4) ◽  
pp. 535 ◽  
Author(s):  
Javier Martin-Broto ◽  
Nadia Hindi ◽  
Antonio Lopez-Pousa ◽  
Javier Peinado-Serrano ◽  
Rosa Alvarez ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Low Dose ◽  
Soft Tissue Sarcomas ◽  
Safety And Efficacy ◽  
Low Dose Radiotherapy

Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study

2020 ◽  
pp. 107815522092407
Author(s):  
Sinan Koca ◽  
Mehmet Beşiroğlu ◽  
Melike Özçelik ◽  
Mustafa Karaca ◽  
Mehmet Bilici ◽  
...  
Keyword(s):  
Overall Survival ◽  
Weight Loss ◽  
Retrospective Study ◽  
Soft Tissue ◽  
Kinase Inhibitor ◽  
Single Agent ◽  
Real Life ◽  
Soft Tissue Sarcomas ◽  
Progression Free Survival ◽  
Free Survival

Purpose Soft tissue sarcomas are associated with a poor prognosis and low chemotherapeutic efficiency. Pazopanib is an orally available multi-tyrosine kinase inhibitor that was explored in patients with non-adipocytic advanced soft tissue sarcomas. The aim of this retrospective study was to evaluate the real life data of single-agent pazopanib efficacy and safety for soft tissue sarcomas in the Turkish population. Materials and methods We evaluated a total of 103 patients (41 males, 62 females) who received pazopanib for advanced non-adipocytic soft tissue sarcomas diagnosis in eight centers of Turkey, retrospectively. The pazopanib dose was 800 mg once daily. Progression-free survival, overall survival, and adverse events were analyzed. Results The median age was 50 years (range, 38–58). Majority of the patients had leimyosarcoma (41%). Median progression-free survival was 4.3 months, and the median overall survival was 10.1 months. The main common toxicities were fatigue, anorexia, weight loss, nausea, hypertension, and grade ≥3 toxicities were fatigue, anorexia, weight loss, and liver disorder. Conclusion Pazopanib is an efficient and tolerable agent and is well tolerated in good performance status patients with relapsed, advanced non-adipocytic soft tissue sarcomas.

scholarly journals Nivolumab plus ipilimumab versus nivolumab in individuals with treatment-naive programmed death-ligand 1 positive metastatic soft tissue sarcomas: a multicentre retrospective study

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Yaolin Chen ◽  
Xiangzhen Liu ◽  
Jijun Liu ◽  
Donghua Liang ◽  
Mingdong Zhao ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Progression Free Survival ◽  
Primary Therapy ◽  
Programmed Death Ligand 1 ◽  
Programmed Death ◽  
Choice Of Treatment ◽  
Treatment Naïve ◽  
Grade 3

Abstract Background Currently, the choice of treatment for individuals with metastatic soft tissue sarcomas (MSTS) presents a significant challenge to clinicians. The aim of this retrospective study was to assess the efficacy and safety of nivolumab plus ipilimumab (NPI) versus nivolumab alone (NIV) in individuals with treatment-naive programmed death-ligand 1 (PD-L1) positive MSTS. Methods Prospectively maintained databases were reviewed from 2013 to 2018 to assess individuals with treatment-naive PD-L1 MSTS who received NPI (nivolumab 3 mg/kg and ipilimumab 1 mg/kg every 3 weeks for 4 doses followed by nivolumab 3 mg/kg every 2 weeks) or NIV (3 mg/kg every 2 weeks) until disease progression, withdrawal, unendurable [AEs], or death. The co-primary endpoints were overall survival (OS) and progression-free survival (PFS). Results The median follow-up was 16.0 months (IQR 14.4–18.5) after targeted intervention. The median OS was 12.2 months (95% confidence interval [CI], 6.1–13.7) and 9.2 months (95% CI, 4.2–11.5) for the NPI and NIV groups, respectively (hazard ratio [HR] 0.49, 95% CI, 0.33–0.73; p=0.0002); the median PFS was 4.1 months (95% CI, 3.2–4.5) and 2.2 months (95% CI, 1.1–3.4) for the NPI and NIV groups, respectively (HR 0.51, 95% CI, 0.36–0.71; p< 0.0001). Key grade 3–5 AEs occurred more frequently in the NPI group than in the NIV group (94 [72.9%] for NPI vs. 35 [27.1%], p< 0.001). Conclusions For treatment-naive PD-L1 positive MSTS, NPI seems to be less tolerated but has a greater survival advantage than NIV as the primary therapy.

Surgical treatment of pulmonary metastases from soft tissue sarcomas: A retrospective study in the Netherlands

1994 ◽  
Vol 56 (3) ◽  
pp. 172-177 ◽  
Author(s):  
Albert N. van Ceel ◽  
Frits Van Coevorden ◽  
Jan D. Blankensteijn ◽  
Harald J. Hoekstra ◽  
Bart Schuurman ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Surgical Treatment ◽  
Soft Tissue ◽  
The Netherlands ◽  
Pulmonary Metastases ◽  
Soft Tissue Sarcomas
Sign in / Sign up

Export Citation Format

Share Document